4/20/2006 | BTCV | S&P boosts Chiron
|
4/11/2006 | BT | Chiron begins phase 1 trial for CHIR-265 in skin cancer patients
|
4/3/2006 | BT | Novartis raises Chiron bid to $48 per share
|
3/16/2006 | BT | Chiron's recall of MMR vaccine impacts company's latest financial results
|
3/15/2006 | BT | ValueAct says Novartis $45 per share offer for Chiron 'grossly inadequate'
|
2/24/2006 | BT | Chiron extends delivery terms for avian bird flu vaccine to U.S. government
|
2/7/2006 | BT | SEC terminates investigation of Chiron
|
1/27/2006 | BT | AVI and Chiron form license agreement for hepatitis C virus
|
1/23/2006 | BT | Cubicin granted marketing approval in Europe
|
12/20/2005 | BT | Market Commentary: Connetics rebounds to end higher; SeraCare plunges 48%; OraSure gains 8%; CuraGen rises by 4%
|
12/19/2005 | BT | Novartis considers buying vaccines-maker Berna to combine with other acquisition target Chiron
|
12/8/2005 | BT | Chiron completes sale of $300 million of stock to Novartis
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
11/1/2005 | BTCV | Moody's puts Chiron on positive review
|
11/1/2005 | BT | Market Commentary: Cell Therapeutics prices $82 million notes to yield 6.75%; Nabi's stock dives on failed clinical trial
|
10/31/2005 | BT | Chiron agrees to be acquired by Novartis for $5.1 billion after price raised
|
10/31/2005 | BTCV | S&P keeps Chiron on positive watch
|
10/31/2005 | CV | Market Commentary: Merger news spurs trades in Placer Dome, Chiron, Leucadia and Level 3
|
10/28/2005 | BT | Chiron adjuvant boosts Avian flu vaccine efficacy, study shows
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/27/2005 | BT | Chiron gets $62.5 million U.S. contract to supply avian flu vaccine
|
10/26/2005 | BT | Merrill keeps Chiron with no rating
|
10/25/2005 | BT | Chiron initiates phase I/II study of cell culture vaccine for flu
|
10/21/2005 | CV | Market Commentary: Wyeth holds up; Ford drops, but GM bonds move higher; Schlumberger off
|
10/20/2005 | CV | Market Commentary: Convertibles market reverses course after strong start; Cypress pulled down; Amgen, biotechs weaker
|
10/19/2005 | BTCV | S&P ups Chiron watch to positive
|
10/18/2005 | BT | Market Commentary: Amgen up; Abgenix, Cell Genesys lower; Chiron drops; Gilead sold on nice quarter; Genzyme seesaws
|
10/17/2005 | BT | Market Commentary: Chiron falls big after closing bell; Biogen, Elan gain; Cephalon up
|
10/11/2005 | CV | Market Commentary: GM, Ford trade mixed, but remain market focus; Skyworks holds up after lower guidance; Inco rises
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|
9/21/2005 | BT | Market Commentary: Nektar, Cyberonics pitch converts; QLT spirals; Chiron players shift to 2.75s; Alkermes stumbles
|
9/21/2005 | CV | Market Commentary: Chesapeake, Devon/Chevron trade; Chiron down; Nektar launches deal; Citi/Genworth prices
|
9/7/2005 | BT | Mature U.S. biotechs have stronger credit than industrials but weaker than Big Pharma, S&P says
|
9/7/2005 | BT | Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
|
9/6/2005 | BT | Chiron says Novartis' $4.5 billion offer for remaining shares 'inadequate'
|
9/6/2005 | BT | Chiron kept by Thomas Weisel at peer perform
|
9/6/2005 | BT | Chiron continued by Merrill Lynch with no rating
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
9/2/2005 | BT | Chiron stock offer price may rise, Merrill says
|
9/2/2005 | BTCV | Moody's affirms Chiron, view developing
|
9/2/2005 | CV | Market Commentary: Albertson's mandatories lag as stock surges; Northwest Airlines, Delta weaken further
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
9/1/2005 | CV | Market Commentary: Airtran, Northwest lead airline convertibles lower; autos sink; Chiron, Phar Pharma gain
|
9/1/2005 | BT | Novartis offers $40 per share for remainder of Chiron
|
9/1/2005 | BT | S&P: Chiron view developing
|
8/31/2005 | BT | Market Commentary: MedImmune shoots up over 10%; Chiron little changed; Glaxo gains on U.S. flu shot OK; Oscient flat
|
7/28/2005 | BT | Chiron reiterated by Merrill Lynch at sell
|
7/20/2005 | BT | Chiron maintained by Merrill Lynch at sell
|
7/15/2005 | BT | Chiron estimated lowered by Merrill
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
6/15/2005 | CV | Market Commentary: Convertibles catch wave of optimism as new Invitrogen deal gains favor; Saks sinks after default notice
|
6/13/2005 | BT | S&P downgrades Chiron
|
4/11/2005 | CV | Market Commentary: El Paso at bat with sweeter terms; Nabi emerges; Ford plummets in wake of warning; Impax steadies
|
3/7/2005 | CV | Market Commentary: Genworth synthetic coming; Cell Therapeutics dives; Celgene rises; Saks bagged up; Lions Gate higher
|
3/2/2005 | CV | S&P: Chiron still on watch
|
3/2/2005 | CV | Market Commentary: Chiron boosted by lifting of U.K. flu vaccine ban; Charter slips further; Maurel & Prom trades up
|
1/12/2005 | CV | New Issue: ABN Amro sells $450,000 10.5% reverse exchangeables linked to Chiron
|
12/20/2004 | CV | Moody's downgrades Chiron
|
12/13/2004 | CV | Chiron changes some payments on 1 5/8% convertibles to cash only
|
11/23/2004 | CV | New Issue: Goldman prices $3.5 million notes exchangeable for Chiron at 2%, up 35%
|
11/19/2004 | CV | New Issue: Goldman prices $10.72 million notes exchangeable for Chiron
|
10/12/2004 | CV | Market Commentary: Apex Silver hovers around par; Amkor firms as bids hit; NPS Pharma, biotechs suffer
|
10/6/2004 | CV | Moody's may cut Chiron
|
10/6/2004 | CV | Market Commentary: Boston Private advances deal; Chiron spreads widen, AMD tighter; Sirius firms on Stern deal
|
10/5/2004 | CV | S&P: Chiron on watch
|
10/5/2004 | CV | Market Commentary: General Mills issue rises; Chiron, Henry Schein fall on flu scare but MedImmune gains
|
10/5/2004 | CV | Market Commentary: General Mills issue rises; Chiron, Henry Schein fall on flu scare but MedImmune gains
|
8/31/2004 | CV | Market Commentary: Six Flags higher on Gates, Redskins owner play; IMC Global rises; Albertson's off
|
8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
6/23/2004 | CV | S&P rates Chiron convertibles
|
6/23/2004 | CV | Market Commentary: Calpine powered up by arbs; Matria gains; Nextel Partners soars; two new deals emerge
|
6/17/2004 | CV | Market Commentary: Chiron goes to 101, Advanced Medical to 103.5; Kellwood to 101.5; Delta reverses, heads up
|
6/17/2004 | CV | New Issue: Chiron $350 million convertible yields 2.75%, up 49.4%
|
6/16/2004 | CV | Chiron $350 million overnight convertible talked at 2.25%-2.75%, up 48%-52%
|
6/16/2004 | CV | Market Commentary: Advanced Medical prices with wide coupon; Kellwood seen offered at 100.5; Delta plunges; JetBlue warns
|
6/15/2004 | CV | Chiron says $649.9 million of LYONs put back
|
5/14/2004 | CV | Chiron to pay upcoming put on LYONs in cash
|
12/16/2003 | CV | Market Commentary: Four deals to price after the close Tuesday; Mentor adds $125 million overnighter
|
7/25/2003 | CV | New Issue: Chiron $450 million overnight convertibles yield 1.625%, up 47.5%
|
7/25/2003 | CV | Market Commentary: Quantum downsizes, sweetens deal as late surge of deals find many players on summer break
|
7/24/2003 | CV | Chiron $450 million overnight convertible talked at 1.5-1.75%, up 45-50%
|
7/24/2003 | CV | S&P rates new Chiron convert A-
|
7/24/2003 | CV | Market Commentary: Health Management breakfast deal reoffered at 98.75 to whet buyers' palate; four deals pricing after close
|
12/12/2001 | CV | Chiron 0% convertibles offer cheap volatility, Deutsche analysts say
|
11/21/2001 | CV | Market Commentary: Convertible market dips slightly, ready for break to digest new issues
|